The Phase-2b study is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA
Dr. Reddy's commits to achieving Net Zero greenhouse gas emissions across its value chain by FY 2045
The investigational therapy uses SteadyTeq, a proprietary copolymer technology from Medincell designed to release olanzapine steadily over time
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
The project focuses on recovering high-quality polycarbonate, a valuable polymer material used in the construction of the filters
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Subscribe To Our Newsletter & Stay Updated
